Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00033917 · ClinicalTrials.gov registry record · Phase 3

Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial

A Phase 3 study of Prematurity and Intraventricular Hemorrhage (IVH), sponsored by Yale University.

Completed
Registry status
Phase 3
Development phase
630
Enrollment target
3
Study locations

NCT00033917 is a Phase 3 study of Prematurity and Intraventricular Hemorrhage (IVH) that has completed, run by Yale University. The registered enrollment target is 630 participants, above the 181-participant average among 21 other Prematurity trials with a reported enrollment target (248% higher). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00033917, a Phase 3 study of Prematurity and Intraventricular Hemorrhage (IVH), has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 3
Development phase
630 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this multicenter trial is to determine if indomethacin prevents bleeding in the brain of very low birth weight preterm infants.

Interventions

  • DRUG placebo
  • DRUG indomethacin

Study Locations (3)

Connecticut

  • Yale University School of Medicine - New Haven

Maine

  • Maine Medical Center - Portland

Rhode Island

  • Brown University School of Medicine - Providence

Trial Details

FieldValue
Enrollment Target 630 participants
Start Date 1989-09
Est. Completion 2012-03
Phase Phase 3

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT00033917

The ClinicalTrials.gov registry entry for NCT00033917 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 630 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 181-participant average among 21 other Prematurity trials with a reported enrollment target (248% higher). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Prematurity appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT00033917 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Connecticut, Maine, Rhode Island.

Frequently Asked Questions

What is clinical trial NCT00033917 about?

NCT00033917 is a clinical study titled "Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial". The purpose of this multicenter trial is to determine if indomethacin prevents bleeding in the brain of very low birth weight preterm infants.

What is the current status of trial NCT00033917?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 630 participants. The study started on 1989-09. Estimated completion is 2012-03.

What conditions does trial NCT00033917 study?

This clinical trial studies the following conditions: Prematurity, Intraventricular Hemorrhage (IVH), Bleeding in the Brain, Very Low Birth Weight Infants.

What interventions are being tested in trial NCT00033917?

The interventions under investigation include: placebo (DRUG), indomethacin (DRUG).

Who is sponsoring clinical trial NCT00033917?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00033917 being conducted?

This trial has 3 study locations across Connecticut, Maine, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prematurity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.